Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 68 publications.

Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the 2024 Parkinson Study Group (PSG) 33rd Annual Meeting; December 5, 2024. Nashville, TN. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis by antipsychotic treatment status in the United States. J Alzheimers Dis. 2024 Dec;102(4):1260-70. doi: 10.1177/13872877241297361

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the Neuroscience Education Institute (NEI) Congress 2024; November 8, 2024. Colorado Springs, CO.

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2024; March 5, 2024. Lisbon, Portugal.

Hong LS, Garcia-Albeniz X, Friesen D, Foskett N, Beau-Lejdstrom R. Use of clinical classifications software to address ICD coding transition in large healthcare databases analyzed via high-dimensional propensity scores. Pharmacoepidemiol Drug Saf. 2024 Jan 24;33(1):e5702. doi: 10.1002/pds.5702

Layton JB, Forns Guzman J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023 Feb 1;46(2):195-208. doi: 10.1007/s40264-022-01260-6

Forns J, Danysh HE, McQuay LJ, Turner ME, Dempsey C, Anthony MS, Demos G, Layton JB. Clinical outcomes and treatment patterns of older adults with dementia‑related psychosis by dementia type in the United States. BMC geriatr. 2022 Oct 6;22(1):784. doi: 10.1186/s12877-022-03489-3.

Bradley Layton J, McQuay L, Forns J, Danysh H, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark. Previously presented at the 2022 American Society of Clinical Psychopharmacology (ASCP).

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0

Johannes CB, Saltus CW, Kaye JA, Calingaert B, Kaplan S, Gordon MF, Andrews EB. The risk of melanoma with rasagiline compared with other antiparkinsonian medications: a retrospective cohort study in the United States Medicare database. Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):643-51. doi: 10.1002/pds.5422

Layton JB, McQuay L, Forns J, Danysh HE, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 American Society of Clinical Psychopharmacology (ASCP); May 31, 2022. Scottsdale, AZ.

Forns J, Danysh H, McQuay L, Turner ME, Dempsey C, Anthony M, Layton B. Natural history of dementia-related psychosis and antipsychotic treatment patterns in older adults in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2022; March 18, 2022. Barcelona, Spain.

Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1

Hellwig K, Magyari M, McDonald T, Gembert K, Wergeland S, Leinonen MK, Aydemir A, Sabido M, Kawai A, Arana A. A multi-country cohort database study to assess pregnancy and infant outcomes in women exposed to cladribine tablets: CLEAR study. Poster presented at the 2021 Digital 37th Conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13, 2021.

Johannes CB, Saltus CW, Kaye JA, Calingaert B, Kaplan S, Gordon MF, Andrews EB. The risk of melanoma with rasagiline compared with other antiparkinsonian medications: a retrospective cohort study in the United States Medicare database. Presented at the Virtual ICPE 2021 Conference; August 24, 2021.

Saltus CW, Kaplan S, Gordon MF, Calingaert B, Andrews EB, Kaye JA, Johannes CB. Validation of diagnosis algorithms for melanoma and nonmelanoma skin cancer among patients with parkinson's disease in the United States Medicare Database. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121

Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Forns J, Layton JB, Ritchey ME. Identifying psychosis in patients with dementia: not a hallucination or delusion, the challenge really exists. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 24(S2):214. doi: 10.1002/pds.4864

Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, D'Onofrio BM, Oberg AS. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One. 2019 Aug 5;14(8):e0214180. doi: 10.1371/journal.pone.0214180

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Didden E-M, Andrews EB, Hellwig K, Hernandez-Diaz S, Magyari M, Margulis AV, Rivero-Ferrer E, Bader-Weder S, Wormser D. A novel approach for active surveillance of pregnancy safety in multiple sclerosis. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):268. doi: 10.1002/pds.4629

Margulis A, Andrews E, Hernandez-Diaz S, Magyari M, Rivero-Ferrer E, Bader-Weder S, Evershed J, Garas M, Wang Q, Wormser D. Design of a multi-source post-marketing study to evaluate pregnancy and infant outcomes in women with multiple sclerosis who were exposed to ocrelizumab during, or within 6 months before, pregnancy. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 25, 2018. Los Angeles, CA.

Vinceti M, Chiari A, Eichmuller M, Rothman KJ, Filippini T, Malagoli C, Weuve J, Tondelli M, Zamboni G, Nichelli PF, Michalke B. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer's dementia in persons with mild cognitive impairment. Alzheimers Res Ther. 2017 Dec 19;9(1):100. doi: 10.1186/s13195-017-0323-1

Vinceti M, Filippini T, Violi F, Rothman KJ, Costanzini S, Malagoli C, Wise LA, Odone A, Signorelli C, Iacuzio L, Arcolin E, Mandrioli J, Fini N, Patti F, Lo Fermo S, Pietrini V, Teggi S, Ghermandi G, Scillieri R, Ledda C, Mauceri C, Sciacca S, Fiore M, Ferrante M. Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environ Health. 2017 Aug 29;16(1):91. doi: 10.1186/s12940-017-0297-2

Basagana X, Esnaola M, Rivas I, Amato F, Alvarez-Pedrerol M, Forns J, Lopez-Vicente M, Pujol J, Nieuwenhuijsen M, Querol X, Sunyer J. Neurodevelopmental deceleration by urban fine particles from different emission sources: a longitudinal observational study. Environ Health Perspect. 2016 Oct;124(10):1630-6.

Krueger WS, Anthony MS, Monz B, Saltus C, Hirst C, Margulis AV, Andrews E. Pregnancy studies assessing drug exposure in populations with multiple sclerosis. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):334.

Julvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivieres S, Brouwer R, Boucher O, Alemany S, Lopez-Vicente M, Suades-Gonzalez E, Forns J, Grandjean P, Sunyer J. Environment and brain development: challenges in the global context. Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256

Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S. Methodological considerations for the implementation of a European mandated retrospective drug utilisation study (DUS) to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322

Perez-Gutthann S, Weatherall M, Garratt C, Pohjanjousi P, Aantaa R, Conti G, Lewis M, Moore N. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):95-6. doi: 10.1002/pds.3838

Johannes CB, Calingaert B, Saltus C, Kaplan S, Grubb E, Kaye JA, Andrews EB. Description of antiparkinsonian drug use in US Medicare claims database: a feasibility assessment. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Aug; 24(S1):85-6.

Roed C, Sørensen HT, Rothman KJ, Skinhoj P, Obel N. Employment and disability pension after central nervous system infections in adults. Am J Epidemiol. 2015 May 15;181(10):789-98. doi: 10.1093/aje/kwu359

Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.

Vilahur N, Fernandez MF, Bustamante M, Ramos R, Forns J, Ballester F, Murcia M, Riano I, Ibarluzea J, Olea N, Sunyer J. In utero exposure to mixtures of xenoestrogens and child neuropsychological development. Environ Res. 2014 Oct;134:98-104. doi: 10.1016/j.envres.2014.07.002

Forns J, Vegas O, Julvez J, Garcia-Esteban R, Rivera M, Lertxundi N, Guxens M, Fano E, Ferrer M, Grellier J, Ibarluzea J, Sunyer J. Association between child cortisol levels in saliva and neuropsychological development during the second year of life. Stress Health. 2014 Apr;30(2):142-8. doi: 10.1002/smi.2504

Casas L, Torrent M, Zock JP, Doekes G, Forns J, Guxens M, Taubel M, Heinrich J, Sunyer J. Early life exposures to home dampness, pet ownership and farm animal contact and neuropsychological development in 4 year old children: a prospective birth cohort study. Int J Hyg Environ Health. 2013 Nov;216(6):690-7. doi: 10.1016/j.ijheh.2012.12.013

López-León S, Rivero E. Statins for prevention of alzheimer's disease: systematic review and meta-analysis. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal, Spain.

Mines D, Tennis PS, Curkendall S, Li A, Peterson C, Andrews EB, Calingaert B, Rothman KJ. Topiramate use in pregnancy and risk of oral clefts. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):320. doi: 10.1111/j.1399-5448.2012.03324.x

Johannes C, Andrews E, McQuay L, Frohlich M, Sims R. Incidence of cerebrovascular accidents in men with prostate cancer. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S271-2.

Vinceti M, Bonvicini F, Rothman KJ, Vescovi L, Wang FY. The relation between amyotrophic lateral sclerosis and inorganic selenium in drinking water: a population-based case-control study. Environ Health. 2010 Dec 1;9(Art. No. 77).

Arana A, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. Authors reply. N Engl J Med. 2010 Nov 4;363(19):1873-4.

Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010 Aug 6;363(6):542-51.

Rothman KJ. Health effects of mobile telephones. Epidemiology. 2009 Sep 1;20(5):653-5.

Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.

Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy. 2009 Mar;29(3):255-62.

Ehrenstein V, Pedersen L, Grijota M, Lauge Nielsen G, Rothman KJ, Toft Sorensen H. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth. 2009;9(1):14.

McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf. 2008 May 1;3(2):123-31.